US Stock Movement: Faeth Therapeutics surges on October 20th: PIKTOR preclinical data + breast cancer
Bitget异动解读2026/10/20 15:35Faeth Therapeutics October 20th Surge Interpretation
Keywords: PIKTOR preclinical data, breast cancer
On October 19th, the company announced that it will present PIKTOR preclinical data at ESMO 2026 on October 23rd. The content includes its effects as a monotherapy and in combination with fulvestrant, oral SERD, and CDK inhibitors, and compares it with giredestrant in two breast cancer xenograft models. The relevant data aims to support the further clinical development of PIKTOR in HR+/HER2− breast cancer.
(Disclaimer: This content is generated by AI summarizing publicly available information for reference only and does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Nvidia is negotiating to invest hundreds of millions of dollars in Firmus
It is reported that EQT has proposed to acquire Qiagen (QGEN.US) for over $50 per share, and KKR is also participating in the bid.
EQT AB is engaged in advanced negotiations to acquire the European molecular diagnostics company Qiagen (QGEN.US), and has submitted a binding offer at over $50 per share.
JPMorgan Asset Management includes bitcoin in long-term assumptions for the first time: 10-year annualized return expected at 10%, but 55% volatility remains a concern
JPMorgan Asset Management has included Bitcoin in its long-term capital market assumptions for the first time, forecasting that its returns over the next decade may outperform stocks, bonds, and gold. This is regarded as a milestone for Bitcoin's acceptance on Wall Street.
Crypto prices
More
